128 / 140
Guía OncoSur de sarcomas de partes blandas
128
>
100. Salech F, Valderrama S, Nervi B, et al. Thalidomide for the treat- ment of metastatic hepatic epithelioid heman-
gioendothelioma: a case report with a long term follow-up. Ann Hepatol 2011;10:99-102.
101. Sumrall A, Fredericks R, Berthold A, et al. Lenalidomide stops progression of multifocal epithelioid heman-
gioendothelioma including intracranial disease. J Neurooncol 2010;97:275-7.
Sarcoma de Kaposi
102. Northfelt DW, Dezube BJ, Thommes P, et al. Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin,
and vincristine in the treatment of AIDS-related Kaposi's sarcoma: results of a randomized phase III clinical
trial. J Clin Oncol 1998;16(7):2445-51.
103. Stewart S, Jablonowski H, Goebel FD, et al. Randomized comparative trial of pegylated liposomal doxorubicin
versus bleomycin and vincristine in the treatment of AIDS-related Kaposi’s sarcoma. International Pegylated
Liposomal Doxorubicin Study Group. J Clin Oncol 1998;16:683-91.
104. Cianfrocca M, Lee S, Von Roenn J, et al. Randomized trial of paclitaxel versus pegylated liposomal doxorubi-
cin for advanced human immunodeficiency virus-associated Kaposi sarcoma. Cancer 2010;116:3969-77.
105. Zustovich F, Ferro A, Toso S. Gemcitabine for the Treatment of Classic Kaposi’s Sarcoma: A Case Series.
Anticancer Res 2013;33(12):5531-4.
106. Tas F, Sen F, Keskin S, et al. Oral etoposide as first-line therapy in the treatment of patients with advanced
classic Kaposi's sarcoma (CKS): a single-arm trial (oral etoposide in CKS). J Eur Acad Dermatol Venereol
2013;27:789.
107. Brambilla L, Labianca R, Boneschi V, et al. Mediterranean Kaposi's sarcoma in the elderly. A randomized
study of oral etoposide versus vinblastine. Cancer 1994;74:2873.
108. Krown SE, Lee JY, Lin L, et al. Interferon-alpha2b with protease inhibitor-based antiretroviral therapy in pa-
tients with AIDS-associated Kaposi sarcoma: an AIDS malignancy consortium phase I trial. J Acquir Immune
Defic Syndr 2006;41:149-53.
109. Uldrick TS, Wyvill KM, Kumar P, et al. Phase II study of bevacizumab in patients with HIV- associated Kapo-
si’s sarcoma receiving antiretroviral therapy. J Clin Oncol 2012;30:1476-83.
110. Stallone G, Schena A, Infante B, et al. Sirolimus for Kaposi’s sarcoma in renal-transplant recipients. N Engl J
Med 2005;352:1317-23.
111. Guenova E, Metzler G, Hoetzenecker W, et al. Classic Mediterranean Kaposi's sarcoma regression with siroli-
mus treatment. Arch Dermatol 2008;144:692.
112. Marfo K, Greenstein S. Antiretroviral and immunosuppressive drug-drug interactions in human immunodefi-
ciency virus-infected liver and kidney transplant recipients. Transplant Proc 2009;41:3796-9.
Angiosarcoma
113. Ravi V, Patel S. Vascular Sarcomas. Springer Science+Business Media New York 2013. Curr Oncol Rep
2013;15:347-55.
114. Italiano A, Cioffi A, Penel N, et al. Comparison of doxorubicin and weekly paclitaxel efficacy in metastatic
angiosarcomas. Cancer 2012;118:3330-6.
115. Fury MG, Antonescu CR, Van Zee KJ, et al. A 14-year retrospective review of angiosarcoma: clinical charac-
teristics, prognostic factors, and treatment outcomes with surgery and chemotherapy. Cancer J 2005;11:241-7.
116. Skubitz KM, Haddad PA. Paclitaxel and pegylated-liposomal doxorubicin are both active in angiosarcoma.
Cancer 2005;104:361-6.
117. Fata F, O’Reilly E, Ilson D, et al. Paclitaxel in the treatment of patients with angiosarcoma of the scalp or face.
Cancer 1999;86:2034-7.
118. Fury MG, Antonescu CR, van Zee KJ, et al. A 14-year retrospective review of angiosarcoma: clinical character-
istics, prognostic factors, and treatment outcomes with surgery and chemotherapy. Cancer J 2005;11:241-7.
119. Schlemmer M, Reichardt P, Verweij J, et al. Paclitaxel in patients with advanced angiosarcomas of soft tissue:
a retrospective study of the EORTC soft tissue and bone sarcoma group. Eur J Cancer 2008;44:2433-6.
120. Penel N, Bui BN, Bay JO, et al. Phase II trial of weekly paclitaxel for unresectable angiosarcoma: the
ANGIOTAX Study. J Clin Oncol 2008;26:5269.